Due to their major role in the tumor cell progression, the levels of the pro-inflammatory cytokines TNF-α and IL-6 were evaluated in dynamics during Nivolumab treatment in three selected serum samples (T1–T3, timepoints of Nivolumab treatment) from each patient at 3-month intervals. The gene discussed is IL6; the disease is neoplasm.